MY163516A - Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents - Google Patents

Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents

Info

Publication number
MY163516A
MY163516A MYPI2010006096A MYPI2010006096A MY163516A MY 163516 A MY163516 A MY 163516A MY PI2010006096 A MYPI2010006096 A MY PI2010006096A MY PI2010006096 A MYPI2010006096 A MY PI2010006096A MY 163516 A MY163516 A MY 163516A
Authority
MY
Malaysia
Prior art keywords
polymorphs
metal chelation
novel salts
chelation agents
desazadesferrithiocin polyether
Prior art date
Application number
MYPI2010006096A
Other languages
English (en)
Inventor
Amy E Tapper
Hugh Y Rienhoff
Stephan D Parent
Patricia Andres
Jason A Hanko
Huamin Zhang
Original Assignee
Ferrokin Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrokin Biosciences Inc filed Critical Ferrokin Biosciences Inc
Publication of MY163516A publication Critical patent/MY163516A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MYPI2010006096A 2008-07-14 2009-07-14 Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents MY163516A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8057208P 2008-07-14 2008-07-14
US15257209P 2009-02-13 2009-02-13

Publications (1)

Publication Number Publication Date
MY163516A true MY163516A (en) 2017-09-15

Family

ID=41550988

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010006096A MY163516A (en) 2008-07-14 2009-07-14 Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents

Country Status (13)

Country Link
US (4) US8063227B2 (https=)
EP (1) EP2303853A4 (https=)
JP (1) JP2011528037A (https=)
KR (1) KR20110039347A (https=)
CN (2) CN103435569B (https=)
AU (1) AU2009271074B2 (https=)
CA (1) CA2728636A1 (https=)
IL (2) IL210294A (https=)
MX (1) MX2011000486A (https=)
MY (1) MY163516A (https=)
NZ (2) NZ605452A (https=)
WO (1) WO2010009120A2 (https=)
ZA (1) ZA201100311B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005034949A1 (en) 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
BRPI0610644B8 (pt) 2005-04-04 2021-05-25 Univ Florida composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
JP5439193B2 (ja) 2007-03-15 2014-03-12 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． デスフェリチオシンポリエーテル類似体
US8063227B2 (en) 2008-07-14 2011-11-22 Ferrokin Biosciences, Inc. Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
BR112012001761A2 (pt) * 2009-07-27 2017-05-09 Ferrokin Bioscience Inc composto de formula i, composto farmacêutica e método de tratamento de uma condição mediada por metal em um indivduo
US9045440B2 (en) 2010-05-04 2015-06-02 Ferrokin Biosciences, Inc. Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents
TW201338777A (zh) * 2011-12-09 2013-10-01 Ferrokin Biosciences Inc 用於治療金屬過載之經口調配物
JP6539046B2 (ja) 2011-12-16 2019-07-03 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． ４’−デスフェリチオシン類似体の使用
WO2014089482A1 (en) * 2012-12-07 2014-06-12 Ferrokin Biosciences, Inc. Polymorph forms of desazadesferrithiocin analogs
EP2970162A1 (en) 2013-03-15 2016-01-20 Ferrokin Biosciences, Inc. Polymorph forms of desazadesferrithiocin analogs
CA2930966A1 (en) * 2013-11-22 2015-05-28 University Of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
KR102497273B1 (ko) 2014-03-06 2023-02-07 피티씨 테라퓨틱스, 인크. 1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염
EP3288557A4 (en) * 2015-04-27 2018-11-07 University of Florida Research Foundation, Inc. Metabolically programmed metal chelators and uses thereof
US10446309B2 (en) 2016-04-20 2019-10-15 Vishay Dale Electronics, Llc Shielded inductor and method of manufacturing
CN107119083A (zh) * 2017-04-28 2017-09-01 江苏梦得新材料科技有限公司 一种生物酶法制备聚二硫二丙烷磺酸钠的方法
CN107174917A (zh) * 2017-05-01 2017-09-19 蒋里军 粘土矿物治霾方法及其摩天大楼治霾烟囱
CN108264892A (zh) * 2017-12-21 2018-07-10 东北农业大学 一种用于释放地下油质材料的表面活性剂的组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083966A (en) 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
AT500490A1 (de) 2001-10-16 2006-01-15 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von substituierten thiazolinen und deren zwischenprodukte
WO2004017959A2 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
AU2003268706A1 (en) 2002-10-01 2004-04-23 Kaneka Corporation PROCESS FOR PRODUCING OPTICALLY ACTIVE Alpha-SUBSTITUTED CYSTEINE OR SALT THEREOF, INTERMEDIATE THEREFOR, AND PROCESS FOR PRODUCING THE SAME
WO2005034949A1 (en) 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
JP2007505044A (ja) 2003-09-09 2007-03-08 ユニバーシティ オブ フロリダ リサーチ ファウンデイション、インコーポレイテッド ポリアミン−金属キレーター接合体
BRPI0610644B8 (pt) * 2005-04-04 2021-05-25 Univ Florida composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
US20080138440A1 (en) 2006-11-29 2008-06-12 Cormedix Inc. Methods of diagnosing and alleviating gadolinium toxicity
US20100137346A1 (en) 2006-12-12 2010-06-03 University Of Florida Research Foundation, Inc. Desferrithiocin analogue actinide decorporation agents
JP5439193B2 (ja) 2007-03-15 2014-03-12 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． デスフェリチオシンポリエーテル類似体
US8063227B2 (en) 2008-07-14 2011-11-22 Ferrokin Biosciences, Inc. Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
BR112012001761A2 (pt) 2009-07-27 2017-05-09 Ferrokin Bioscience Inc composto de formula i, composto farmacêutica e método de tratamento de uma condição mediada por metal em um indivduo
US20120184586A1 (en) 2009-08-25 2012-07-19 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues and uses thereof
US9045440B2 (en) 2010-05-04 2015-06-02 Ferrokin Biosciences, Inc. Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents

Also Published As

Publication number Publication date
AU2009271074B2 (en) 2014-10-30
CA2728636A1 (en) 2010-01-21
US20120202857A1 (en) 2012-08-09
US8710087B2 (en) 2014-04-29
EP2303853A4 (en) 2011-08-10
WO2010009120A2 (en) 2010-01-21
US20120270911A1 (en) 2012-10-25
NZ590302A (en) 2013-02-22
EP2303853A2 (en) 2011-04-06
IL210294A (en) 2014-04-30
AU2009271074A1 (en) 2010-01-21
US8846731B2 (en) 2014-09-30
US20100137383A1 (en) 2010-06-03
CN103435569A (zh) 2013-12-11
US20110160257A1 (en) 2011-06-30
NZ605452A (en) 2014-05-30
US8829197B2 (en) 2014-09-09
CN102149700A (zh) 2011-08-10
ZA201100311B (en) 2011-12-28
US8063227B2 (en) 2011-11-22
IL210294A0 (en) 2011-03-31
MX2011000486A (es) 2011-08-03
CN103435569B (zh) 2015-08-19
WO2010009120A3 (en) 2010-04-22
IL231558A0 (en) 2014-04-30
WO2010009120A8 (en) 2011-02-24
JP2011528037A (ja) 2011-11-10
KR20110039347A (ko) 2011-04-15

Similar Documents

Publication Publication Date Title
MY163516A (en) Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
WO2011140232A3 (en) Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents
WO2011017054A3 (en) Prodrugs of desazadesferrothiocin polyether analogues as metal chelation agents
PH12012500620A1 (en) Compounds
IN2012DN01233A (https=)
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
MX2009010407A (es) Derivados fluorados de deferiprona.
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
IL193252A0 (en) N-hydroxyacrylamide compounds
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
EP2131849A4 (en) COMPOSITIONS AND METHODS OF DISTRIBUTING AGENTS AGAINST CANCER
MX2011011618A (es) Agentes terapeuticos 713.
EA201000141A1 (ru) Новые триазены для лечения рака
MX2010001303A (es) Compuestos terapeuticos.
TN2011000678A1 (en) Fluorinated derivatives of 3-hydroxypyridin-4-ones
MX2009005912A (es) Derivados de etilamina-fenilo heterociclilo sustituidos, su preparacion y uso como medicamentos.
MX342465B (es) Metodos para tratar enfermedades hematologicas usando 6-ciclohexil-1-hidroxi-4-metil-2(1h)-piridona.
MX2007013449A (es) Composicion cosmetica para despigmentacion o aclaracion que comprende al menos una oxazolina como un ingrediente activo.
IL191690A0 (en) Therapy of malignant neoplasias
ZA200706705B (en) Phenylbenzoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic uses thereof
SI1904511T1 (sl) Homogemcitabini
UA95260C2 (ru) Производное 4-(3-аминопиразол)пиримидина и его применение для лечения злокачественного новообразования
TN2010000447A1 (en) Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists